Given the availability of a monoclonal antibody against ANGPTL3 already used in patients with familial hypercholesterolemia, these results warrant further investigation of whether ANGPTL3 inhibition has therapeutic potential in ovarian cancers. Here, ANGPTL3 is linked to familial hypercholesterolemia.